When administered intravenously, its connection with the preparation of the plasma proteins does not exceed 10%. 5 minutes after intravenous bolus Urografin 60% at a dose of 1 ml per kg body weight is achieved drug concentration in plasma corresponding to 3.2 g of iodine per liter. During the 3 hours after the administration is observed a relatively rapid decrease in concentration, then a gradual decrease with a half-life of 1-2 hours.
Amidotrizoat not penetrate into erythrocytes. After estrogen testosterone combination meds intravascular injection is rapidly distributed in the intercellular substance. Do not cross the intact blood-brain barrier only in minimal quantities enters breast
Metabolism and elimination
When administered in diagnostic doses amidotrizoat subjected to glomerular filtration in the kidneys. About 15% of the injected drug is excreted unchanged in the urine in the 30 minutes after administration, and more than 50% – within 3 hours.
The clinically used dose range observed kinetics of distribution and elimination Urografin does not depend on the dose. This means that doubling or 2-fold reduction in dose Urografin leads to a twofold increase or decrease in the content of the contrast agent into the bloodstream and eliminable quantity in grams per unit of time. However, due to an increase in osmotic diuresis while doubling the dose of the contrast agent concentration in urine did not increase to the same extent.
Patients with renal insufficiency
In case of violation of renal function amidotrizoevaya acid can be eliminated by the liver extrarenal, albeit with slower speeds. Nephrotropic contrast agents can be readily removed from the body via the extracorporeal hemodialysis. Regardless of the place of administration Urografin complete elimination of the contrast agent takes place guaranteed for even a short time of fabrics.
Intravenous and retrograde urography.
In addition, for all angiographic studies, as well as for arthrography, intraoperative cholangiography, endoscopic retrograde cholangiopancreatography (ERCP), sialography, fistulography, gisterosaliingografii and others.
Severe hyperthyroidism, decompensated heart failure.
Do not use Urografin for myelography, ventriculography and cisternography, in connection with possible neurotoxic events.
Hysterosalpingography not carried out during pregnancy or in the presence of acute inflammatory processes in the pelvic region.
Endoscopic retrograde cholangiopancreatography estrogen testosterone combination meds is not carried out in acute pancreatitis.
The use caution
with extreme care use in patients with hypersensitivity to iodine-containing contrast agents, serious disorders of the liver or kidney problems, cardiovascular disease, emphysema clear, severe general condition, cerebral arteriosclerosis, decompensated diabetes, cerebral vasospasm, subclinical hyperthyroidism, nodular goiter and generalized myeloma.
Pregnancy and lactation
A study of toxic effects amidotrizoat meglumine or sodium on reproductive function does not indicate Urografin capacity at its unintentional introduction during pregnancy cause teratogenic or embryotoxic effects.
Sufficient evidence of the safety of use in pregnant women Urografin not. As far as possible, in any case should be avoided during pregnancy radiation exposure must be carefully weighed against the benefits and risks of the X-ray examination without or in the presence of radiographic contrast agents.
Contrast agents such as Urografin, which are characterized by the renal route of elimination, penetrate into breast milk in very small amounts.
According to available data, the risk of infants from their mothers administration diatrizoic acid salts is small.
Dosing and Administration
- Preparing the patient for the procedure
In angiography, urography and abdominal cavity to facilitate diagnosis is recommended to thoroughly clean the patient’s stomach. Therefore, in the last two days before the test to avoid the food that causes flatulence (especially beans, salads, fruit, fresh bread and black, as well as any vegetables in their raw form). Last meal of the day before the survey is to be no later than 18 hours. In addition, it is advisable to take a laxative in the evening. Infants and young children long intervals in food intake, as well as the appointment of laxatives are contraindicated.
Because the excitement, fear and pain can cause side effects or intensify the reaction to the contrast agent, before the research is recommended to the patient a soothing conversation or appoint sedative medications.
Patients with generalized estrogen testosterone combination meds myeloma, diabetes mellitus with nephropathy, polyuria, oliguria, hyperuricemia, as well as infants and young children, elderly patients should be adequately hydrated. Prior studies should be eliminated violations of water-electrolyte metabolism (if any).